glp 1 and cannabinoids Putative mechanisms underlying CNS access of GLP-1 analogues. Although Cannabidiol and Other Non-Psychoactive Cannabinoids

This allowed us to gauge the product's efficacy, taste, mixability, and any potential side effects

& Lin, Y

doi: 10.1016/j.phrs.2021.105874

In descending order, the medications used included serotonin-norepinephrine reuptake inhibitors (used by 182 patients), gabapentin (155 patients), tricyclic antidepressants (134 patients), trazodone (59 patients), pregabalin (46 patients), muscle relaxants (45 patients), montelukast (26 patients), -blockers (21 patients), aripiprazole (12 patients), histamine 1 or histamine 2 blockers (11 patients), naltrexone (8 patients), amphetamine- or methylphenidate-based stimulants (8 patients), midodrine (7 patients), fludrocortisone (6 patients), non-amphetamine stimulants (4 patients), pyridostigmine (4 patients), -blockers (1 patient), and droxidopa (1 patient)